Equities

Oxford Biomedica PLC

OXB:LSE

Oxford Biomedica PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)328.00
  • Today's Change28.00 / 9.33%
  • Shares traded1.14m
  • 1 Year change-20.96%
  • Beta1.4637
Data delayed at least 20 minutes, as of May 03 2024 16:41 BST.
More ▼

Profile data is unavailable for this security.

About the company

Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.

  • Revenue in GBP (TTM)89.54m
  • Net income in GBP-157.49m
  • Incorporated1996
  • Employees714.00
  • Location
    Oxford Biomedica PLCWindrush Court, Transport WayOXFORD OX4 6LTUnited KingdomGBR
  • Phone+44 18 6578 3000Fax+44 18 6578 3001
  • Websitehttps://www.oxb.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		OXB:LSE since
announced		Transaction
value
ABL Europe SASDeal completed20 Sep 202320 Sep 2023Deal completed35.82%16.02m
Data delayed at least 20 minutes, as of May 03 2024 16:41 BST.

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Kuros Biosciences AG29.41m-12.03m210.92m80.00210.92m80.00
Ryvu Therapeutics SA9.25m-18.19m221.90m230.00221.90m230.00
Nanobiotix SA25.72m-33.98m224.28m102.00224.28m102.00
Bioventix PLC13.60m8.67m225.75m16.00225.75m16.00
PharmaSGP Holding SE83.49m12.83m230.05m89.00230.05m89.00
Euroapi SA872.00m-162.35m233.15m3.67k233.15m3.67k
Selvita SA69.49m13.83m255.92m847.00255.92m847.00
Hyloris Pharmaceuticals SA2.41m-13.49m280.37m24.00280.37m24.00
Niox Group PLC36.80m9.50m296.77m85.00296.77m85.00
Oxford BioMedica plc89.54m-157.49m300.00m714.00300.00m714.00
Nykode Therapeutics ASA10.29m-28.04m316.19m173.00316.19m173.00
Idorsia Ltd161.81m-327.73m336.21m1.36k336.21m1.36k
Carbios SA20.54k-23.30m346.01m134.00346.01m134.00
Medincell SA9.28m-22.61m357.27m138.00357.27m138.00
Deva Holding AS188.27m56.88m372.63m2.93k372.63m2.93k
Data as of May 03 2024. Currency figures normalised to Oxford Biomedica PLC's reporting currency: UK Pound GBX

Institutional shareholders

38.54%Per cent of shares held by top holders
HolderShares% Held
Vulpes Investment Management Pte Ltd.as of 23 Oct 20238.44m8.44%
Liontrust Investment Partners LLPas of 15 Mar 20238.04m8.05%
M&G Investment Management Ltd.as of 15 Mar 20235.07m5.07%
Global Alpha Capital Management Ltd.as of 15 Mar 20233.88m3.88%
Hargreaves Lansdown Asset Management Ltd.as of 15 Mar 20233.03m3.03%
The Vanguard Group, Inc.as of 15 Mar 20232.71m2.71%
Charles Schwab Investment Management, Inc.as of 02 Dec 20232.53m2.53%
Banque Pictet & Cie SAas of 02 Dec 20231.92m1.92%
Threadneedle Asset Management Ltd.as of 02 Dec 20231.59m1.59%
BlackRock Investment Management (UK) Ltd.as of 02 Dec 20231.32m1.32%
More ▼
Data from 31 Dec 2023 - 11 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.